8-K: CV Sciences Reports Q3 2026 Results, Revenue Stable, Margins Improve

CV Sciences announced its third quarter 2026 financial results, reporting $3.0 million in revenue, stable sequentially but down year-over-year, with improved gross margins and a move to positive adjusted EBITDA.

Summary

• CV Sciences reported $3.0 million in revenue for the third quarter of 2026, which is flat compared to the second quarter of 2026 but a decrease from $3.3 million in the third quarter of 2025.
• Gross margin improved to 50.0% in Q3 2026, up from 48.5% in Q3 2025 and 48.6% in Q2 2026.
• Operating expenses were reduced by 11.6% year-over-year to $1.6 million in Q3 2026.
• The company achieved positive adjusted EBITDA of $32,000 in Q3 2026, a significant improvement from adjusted EBITDA losses of $118,000 in Q3 2025 and $132,000 in Q2 2026.
• Cash balance stood at $0.3 million at the end of the quarter.
• Working capital increased to $0.7 million, up from $0.1 million at year-end.
• Products launched since January 2023 accounted for 48% of Q3 2026 net revenue.
• The company is monitoring potential updates to federal provisions for hemp-derived cannabinoid products, scheduled for December 11, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously neutral to slightly negative sentiment, reflecting a stabilization of revenue but a year-over-year decline, alongside ongoing regulatory uncertainties.

Positives

• Improved gross margin to 50.0% in Q3 2026.
• Reduced operating expenses by 11.6% year-over-year to $1.6 million in Q3 2026.
• Achieved positive adjusted EBITDA of $32,000 in Q3 2026, reversing losses from prior periods.
• Increased working capital to $0.7 million.
• New products launched since January 2023 contributed 48% of Q3 2026 revenue, indicating successful product innovation.
• Expanded the +PlusHLTH portfolio with personalized wellness solutions for healthy aging.

Negatives

• Revenue decreased by 7.0% to $3.0 million in Q3 2026 compared to $3.3 million in Q3 2025.
• Sales volume decreased by 4.7% in Q3 2026 compared to Q3 2025.
• Average sales prices also decreased.
• Cash balance remains low at $0.3 million.

Risks

• Ongoing regulatory challenges at the federal level and in certain states are impacting sales.
• Potential updates to restrictive federal provisions for hemp-derived cannabinoid products, scheduled for December 11, 2026, could further impact the business.
• The company faces pressure on revenue due to the regulatory environment.

Future Outlook

The company remains focused on strengthening its established brands, expanding into broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities for sustainable growth and long-term shareholder value. They are also actively monitoring potential updates to federal regulations concerning hemp-derived cannabinoid products.

Management Comments

• Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue.
• We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026.
• These results reflect our continued focus on cost discipline, operational efficiency, and improving the underlying profitability of our business.
• At the same time, we continue to advance our product innovation and diversification strategy.
• Looking ahead, we remain focused on strengthening our established brands, expanding our presence in broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities that support sustainable growth and long-term shareholder value.

Industry Context

StockSavvy.ai notes that CV Sciences operates in the competitive consumer wellness sector, particularly within hemp-derived products. The company's performance is significantly influenced by evolving federal and state regulations, which are a major factor for many companies in this space. The reported revenue stabilization and margin improvement, despite a year-over-year decline, suggest a focus on operational efficiency and product mix in a challenging market.

Legal Proceedings

• The company recognized a gain on legal settlement of $0.5 million in Q3 2026 related to an action against their former legal counsel, Procopio.

Stakeholder Impact

• Shareholders: The company's focus on operational efficiency and achieving positive adjusted EBITDA aims to improve long-term shareholder value, though revenue decline and low cash balance present ongoing concerns.
• Employees: Continued focus on attracting and retaining talent through stock-based compensation is noted.
• Suppliers/Creditors: Improved working capital may indicate better management of payables and inventory, potentially easing supplier relations.

Next Steps

• Continue to strengthen established brands.
• Expand presence in broader science-based wellness categories.
• Maintain disciplined capital allocation.
• Pursue strategic opportunities for sustainable growth.
• Monitor potential updates to federal provisions for hemp-derived cannabinoid products.

Key Dates

Recommendation

The company shows signs of operational improvement with increased gross margins and positive adjusted EBITDA, but the year-over-year revenue decline and low cash balance, coupled with significant regulatory uncertainty, warrant a cautious 'hold' stance. Further clarity on regulatory developments and sustained revenue growth are needed for a more positive outlook.

Keywords

hemp extracts, consumer wellness, financial results, adjusted EBITDA, gross margin, operating expenses, product innovation, regulatory update